Organisation paid for research Program year 2025 Source: CMS Open Payments

Shepherd Center Inc

Neither a doctor nor a teaching hospital

Research payments

$1,121,664

392 payments

Through program year 2025, Shepherd Center Inc is reported as receiving $1,121,664 in research payments, across 392 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$137,447	107
2024	Research	$131,380	82
2023	Research	$330,900	108
2022	Research	$348,981	39
2021	Research	$53,727	5
2020	Research	$36,416	11
2019	Research	$82,813	40

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $432,429 36 payments
Biogen, Inc. $210,646 3 payments
Roche Products Limited $126,956 243 payments
Boston Scientific Corporation $114,111 28 payments
Adamas Pharmaceuticals, Inc. $105,497 47 payments
F. Hoffmann-La Roche AG $43,537 9 payments
SPR Therapeutics, Inc $25,036 3 payments
Novartis Pharmaceuticals Corporation $22,371 3 payments
AbbVie, Inc. $21,774 10 payments
Jazz Pharmaceuticals Inc. $17,057 6 payments

Studies the money was for Research payments · program years 2019–2025

Assessing Disease Activity in Minority Patients With Relapsing Multiple Sclerosis Using Ocrelizumab $324,831 24 payments
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple SclerosisSwitching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment $167,808 1 payment
Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $126,956 243 payments
Ensemble $70,911 8 payments
A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $70,258 31 payments
Rapid $57,795 12 payments
Rapid $48,217 12 payments
Ocrelizumab in Patients With RMS $43,537 9 payments
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration $38,255 1 payment
A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment $35,239 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.